Skin biopsy coding decides whether your most routine dermatology procedure gets paid or sits in a denial queue. The codes changed completely in 2019, yet many practices still report them incorrectly, and the cost shows up as denied claims, delayed cash, and audit exposure on a procedure you perform every day. Three biopsy methods exist, tangential, punch, and incisional, with six codes covering the work. One hierarchy rule decides which primary code you report, the diagnosis you pair with it decides whether the payer accepts medical necessity, and your documentation decides whether either holds up under review.
This guide gives dermatology providers the rules that protect the payment, including how to handle multiple biopsies, what is bundled into each code, which ICD-10 diagnosis to attach, and the documentation that keeps claims clean. Practices that prefer to hand this off entirely can rely on our dermatology medical billing services, but every provider on the chart should understand the rules below, because the documentation that supports them starts at the point of care.
The Biopsy Code Set You Need to Know
Back in 2019, the CPT codes for skin biopsies changed completely. The old codes 11100 and 11101 are gone. They were retired. In their place, we now have six codes organized by biopsy method .
Here is the full set.
Tangential biopsy codes
- 11102: Tangential biopsy of skin, single lesion
- 11103: Each separate or additional tangential lesion (add-on code)
Punch biopsy codes
- 11104: Punch biopsy of skin, including simple closure when performed, single lesion
- 11105: Each separate or additional punch lesion (add-on code)
Incisional biopsy codes
- 11106: Incisional biopsy of skin, including simple closure when performed, single lesion
- 11107: Each separate or additional incisional lesion (add-on code)
Tangential biopsy means shave, scoop, saucerize, or curette techniques. The sample comes from the surface of the skin and is partial thickness. Punch biopsy uses a circular tool to remove a cylindrical full thickness sample. Incisional biopsy uses a scalpel to remove a larger full thickness sample, often wedge shaped .
The Most Important Rule About Multiple Biopsies
Here is where most practices mess up. You cannot just report a primary code for each different biopsy technique you perform.
The guidelines are very clear. When you perform multiple biopsies during the same encounter, you report only one primary biopsy code.
That primary code must be the one representing the most invasive technique used. Then you add the corresponding add-on codes for every additional biopsy, regardless of technique.
You have one chance to pick the primary code. Pick the wrong one, and your claim is wrong.
Hierarchy from least to most invasive:
- Tangential biopsy (11102) is the least invasive
- Punch biopsy (11104) is moderately invasive
- Incisional biopsy (11106) is the most invasive
|
A Closer Rule: List the Highest Valued Code First
The hierarchy you just read holds for sessions that contain only biopsies, but the exact CPT instruction is to list the highest valued code first, which for biopsies runs incisional, then punch, then tangential. In almost every biopsy-only session the most invasive method is also the highest valued, so the two rules agree. They stop agreeing the moment a separately reportable non-biopsy procedure enters the same session. When a biopsy is performed alongside a destruction or an excision on a different lesion, you list the highest valued code of all procedures first, and that lead code may not be the biopsy.
Example. Your dermatologist performs a punch biopsy of a lesion on the chest and, on three separate actinic keratoses of the face, performs chemosurgery destruction. You list 11104 first because its payment of roughly 121.85 dollars exceeds the destruction code 17000 at roughly 66.80 dollars, then you report 17000 with modifier 51 for each additional destroyed lesion. The biopsy leads the claim even though destruction is a different procedure family, because ordering follows value, not procedure type.
What These Codes Pay in 2026
Reimbursement follows invasiveness, which is why the primary code rule matters to your bottom line and not just to compliance. The 2026 national non-facility payment for a punch biopsy under 11104 is roughly 121.85 dollars, and the add-on codes pay a reduced amount per additional lesion. Incisional biopsy under 11106 carries the highest relative value of the three methods, tangential under 11102 the lowest, with punch in the middle. These are national Medicare amounts and they shift with locality adjustment and annual fee schedule updates, so confirm the current figure for your region using the CMS Physician Fee Schedule Look-Up Tool before you quote a number to a provider or a patient. The reason this matters for coding accuracy is simple. When you report the wrong primary code, you are not only risking a denial, you are often leaving the higher-valued code unbilled, which is a silent revenue leak that never appears as a denial at all.
What Is Bundled into the Biopsy Codes?
This matters a lot for your bottom line. Each biopsy code includes certain services that you cannot bill separately.
- Simple closure is included. When the physician performs a punch or incisional biopsy and closes the wound with a simple suture, you cannot bill an additional repair code. The closure is part of the biopsy package .
- Local anesthesia is included. Numbing the skin before the biopsy is part of the procedure. Do not bill anesthesia separately.
- Hemostasis is included. Any bleeding control is part of the biopsy.
- Procurement of tissue is included. The act of taking the sample is obviously part of the biopsy.
- The only time you might bill something extra is if the closure is not simple. If the physician performs an intermediate or complex repair, that may be separately reportable. But that is rare for standard skin biopsies.
Linking Each Biopsy to the Right Diagnosis
A skin biopsy code only gets paid when it is paired with an ICD-10-CM diagnosis that proves medical necessity, and the pairing is where many clean-looking claims fail. The rule that catches practices off guard is sequencing. At the moment of biopsy you usually do not have a confirmed pathology result, so you code the most specific diagnosis the record supports at that time, not the disease you suspect. That often means a sign or finding such as a changing or suspicious lesion, or a neoplasm of uncertain behavior, rather than a malignancy code. You do not assign a malignant diagnosis until pathology confirms it.
Common pairings for skin biopsy claims:
Melanocytic nevus, including a suspicious or changing mole: D22 series by site.
Neoplasm of uncertain behavior of skin: D48.5, and neoplasm of unspecified behavior of skin: D49.2. These are appropriate when the lesion is suspicious and pathology has not yet returned.
Seborrheic keratosis: L82.1, with inflamed seborrheic keratosis at L82.0.
Other benign neoplasm of skin: D23 series by site.
Non-melanoma skin cancer, basal cell and squamous cell, confirmed by pathology: C44 series by site.
Malignant melanoma, confirmed by pathology: C43 series by site.
The denial rule to give every provider is direct. A benign diagnosis paired with a malignant-intent procedure, or a confirmed malignancy code attached before pathology supports it, is an automatic denial and an audit flag. Once the pathology report returns, update the encounter to the confirmed diagnosis so the record, the claim, and the path report all agree. When that pairing is wrong at scale, it is exactly the leak our denials management work is built to recover, but the cleaner fix is attaching the correct diagnosis at submission.
Biopsy Versus Excision: Know the Difference
This is one of the most common coding errors in dermatology. A biopsy and an excision are not the same thing, and you cannot use the codes interchangeably.
A biopsy is a sampling procedure. The physician removes part of a lesion or a small sample for diagnostic purposes. The goal is to find out what the lesion is. Complete removal is not the objective .
An excision is a removal procedure. The physician removes the entire lesion along with a margin of normal surrounding tissue. The goal is complete removal, often for therapeutic reasons.
Here is where it gets tricky. Sometimes a physician starts with a biopsy and then, after seeing the pathology report, goes back and performs an excision. Those are separate services and can be billed separately with the appropriate modifiers.
But if the physician performs a shave removal that is intended to completely remove a benign lesion for therapeutic reasons, that is not a biopsy. That is a shave removal. Use codes 11300 through 11313 for shave removals of benign lesions, not the biopsy codes .
The NCCI guidelines are very clear about this. The codes for lesion removal include the procurement of tissue from the same lesion by biopsy at the same patient encounter. You cannot report biopsy codes separately with lesion removal codes if they are performed on the same lesion during the same encounter. However, if the biopsy is performed on a different lesion than the removal procedure, separate reporting is allowed .
Site Specific Biopsy Codes
Here is something many coders miss. The biopsy codes 11102 through 11107 are not always the correct codes to use.
If there is a more specific biopsy code elsewhere in CPT for the specific site, you must use that site specific code instead. Do not default to 11102 through 11107 just because they say skin biopsy .
For example, biopsy codes exist for specific sites like the cervix, the uterus, the prostate, and the breast. Those have their own code families. For skin, the 111xx codes are generally correct, but always check the index first.
The documentation should clearly support the location of each biopsy. If your pathologist draws a picture or writes a clear verbal description, that helps support the code selection .
Pathology Coding: What Happens After the Biopsy
Once the tissue is removed, it goes to the pathology lab. That is a separate service with separate codes.
The pathology codes for skin biopsy specimens generally fall into the 88300 series. Most routine skin biopsy specimens are coded as 88305, which is for surgical pathology, gross and microscopic examination, Level IV.
Common specimens that get 88305 include skin biopsies, polyps, and other small tissue samples. The pathologist performs both a gross examination, looking at the tissue with the naked eye, and a microscopic examination, looking at slides under the microscope.
Do not assume that every skin biopsy automatically gets 88305. The level depends on the complexity of the specimen and the work required. But for most routine dermatology skin biopsies, 88305 is the correct code.
The global payment for 88305 includes both the technical component, which is the slide preparation, and the professional component, which is the pathologist’s interpretation. Some practices bill globally. Others split the components depending on who does what work.
The Anti Markup Rule for Pathology
This is a compliance issue that every dermatology practice needs to understand.
If your practice sends slides to an outside lab for preparation but your own physician reads them, you are subject to the anti-markup rules for purchased diagnostic tests. You can still bill Medicare, but there are limits on what you can collect.
When you bill Medicare for both the technical component (slide preparation) and the professional component (interpretation), and the slides were prepared by an outside lab, the technical component must be submitted on a separate claim form. Your reimbursement for the technical component is limited to the lesser of the outside lab’s charge to you or the Medicare fee schedule amount.
If the pathology service is performed on site, meaning in your practice location, the anti-markup rules do not apply the same way. You can bill for the service without those limitations. This is why many dermatology practices have brought pathology services in house .
The Relationship Between Biopsy and Destruction
Here is a scenario that comes up all the time. A physician sees a suspicious lesion, performs a biopsy to confirm the diagnosis, and then upon receiving the pathology report confirming malignancy, performs destruction of the lesion in a separate session.
That is two separate services. The biopsy is billable. The destruction is billable. Use modifier 58 to indicate that the destruction was a staged or planned procedure following the diagnostic biopsy.
But what if the physician performs the destruction at the same time as the biopsy? That is different. The NCCI guidelines say that if a removal procedure is begun by one method but is converted to another method to complete the procedure, only the code describing the completed procedure may be reported.
For example, if the physician starts a tangential biopsy but then realizes the lesion is more concerning and converts to a full excision, you code only the excision. The biopsy is not separately billable because it was part of the same procedure.
Here is another important point. If the physician performs destruction of a lesion and sends a portion of the tissue to pathology, that is not a separate biopsy. The biopsy is considered an integral component of the definitive procedure, which in this case is the destruction. You can only report the destruction code.
The documentation must clearly indicate that the definitive procedure was the destruction with a portion of the tissue sent to pathology for examination. That supports reporting only the destruction code.
Modifiers You Need for Skin Biopsy Coding
Several modifiers come into play with skin biopsies.
- Modifier 59 (Distinct Procedural Service). Modifier 59 and the X{EPSU} set (Distinct Procedural Service). Use these to show that a procedure was separate and distinct from another procedure on the same day, most often to unbundle a biopsy from a destruction or excision performed on a different lesion or site. Modifier 59 is the general indicator, but many payers now require the more specific subset: XE for a separate encounter, XS for a separate structure or lesion, XP for a separate practitioner, and XU for an unusual non-overlapping service. For two biopsies on different lesions, or a biopsy and a destruction on different sites, XS is usually the precise choice. Check the payer policy, because submitting 59 where the payer expects XS is a common, avoidable denial.
- Modifier 58 (Staged or Related Procedure). Use this when a procedure is planned or anticipated as part of a staged treatment plan. A diagnostic biopsy followed by a planned excision or destruction in a subsequent session would use modifier 58 on the later procedure.
- Modifier 51 (Multiple Procedures). This is used when multiple procedures are performed during the same surgical session. However, with the add on code structure of the biopsy codes, modifier 51 is often not needed because add on codes are exempt.
- Modifier 25 (Significant, Separately Identifiable E/M Service). Use this when an evaluation and management service is performed on the same day as a procedure and is significant and separately identifiable. The documentation must support that the E/M service went beyond the usual pre procedural workup.
NCCI Edits That Affect Skin Biopsy Coding
The National Correct Coding Initiative has specific rules that impact how you report skin biopsies.
Procedure to procedure edits
These define pairs of codes that should not be reported together on the same date of service. For example, a biopsy code paired with an excision code on the same lesion would be subject to an edit. Modifier 59 may be used to bypass the edit when the procedures were performed on separate and distinct lesions.
Medically unlikely edits (MUE)
Medically unlikely edits (MUE). These define the maximum units of service reportable for a code on a single date of service. The primary biopsy codes carry a low MUE because only one primary code is correct per encounter, while the add-on codes 11103, 11105, and 11107 carry higher limits because they can repeat per lesion.
CMS revises MUE values and their adjudication indicators quarterly, so confirm the current limit and indicator against the published CMS MUE table rather than relying on a fixed number. If you exceed the limit, the extra units deny, and while you can appeal with records and a letter of medical necessity, staying within the current MUE from the start is the cleaner path.
Documentation Requirements for Clean Claims
Your operative note or procedure note needs to include specific information to support the codes you bill.
- For each lesion. Document the location of the lesion. Describe the appearance and reason for biopsy. Document the technique used, tangential, punch, or incisional. Note whether simple closure was performed.
- For multiple lesions. Clearly distinguish each lesion. Use a system like right arm, left arm, back, or use a diagram. Document the technique used for each lesion separately.
- The medical necessity statement. Why was the biopsy needed? Suspicious appearance? Change in size or color? Family history of skin cancer? This information supports the medical necessity of the procedure.
- The pathology requisition. The requisition form sent with the specimen should match the documentation in the medical record. Consistent information across the record and the requisition prevents confusion and supports the claim.
- The final diagnosis. Once the pathology report comes back, the final diagnosis should be added to the record. This closes the loop and supports that the biopsy was medically necessary.
Common Coding Mistakes and How to Avoid Them?
Using multiple primary codes
This is the most common error. When you perform multiple biopsies using different techniques, you report only one primary code. The primary code must be the one representing the most invasive technique. Then you use add on codes for all additional biopsies.
Billing biopsy with destruction on the same lesion in the same session
The biopsy is bundled into the destruction. You cannot bill both. Only the destruction code is reportable.
Using biopsy codes for therapeutic shave removals
If the physician is removing a benign lesion completely for therapeutic reasons, that is not a biopsy. Use the shave removal codes 11300 through 11313.
Billing simple closure separately
Simple closure is included in punch and incisional biopsy codes. Do not bill an additional repair code unless the closure is intermediate or complex.
Failing to link each biopsy to its specific diagnosis
Each add on code needs to point to the diagnosis that justifies the biopsy on that specific lesion. The documentation must support that each lesion was separately evaluated and biopsied.
Not documenting lesion locations clearly
The specific location of each biopsy should be clearly supported by documentation. A verbal description or a drawing help support the code selection and justifies multiple units.
The Point-of-Care Checklist for Providers
Most biopsy denials trace back to something the provider could have captured in under a minute at the time of the procedure. Before you move to the next patient, confirm the chart records the number of lesions biopsied, the technique used for each one, the anatomic site of each lesion described distinctly, the lesion measurement taken before anesthesia, and a medical-necessity statement explaining why the biopsy was warranted, such as a suspicious appearance, a change in size or color, or a personal or family history of skin cancer. Make sure the pathology requisition matches the operative note exactly, because a mismatch between the two is enough to stall the claim. When you capture these at the point of care, your coder has everything needed to select the correct primary and add-on codes and attach the right diagnosis, which is the difference between a clean claim and a rework.
Frequently Asked Questions
Can I bill 11102 for a shave removal of a seborrheic keratosis?
No. A shave removal of a benign lesion for therapeutic purposes is not a biopsy. It is a shave removal. Use codes 11300 through 11313 based on the size of the lesion. The biopsy codes are for diagnostic sampling, not therapeutic removal.
How do I code a punch biopsy that is sent to pathology and the patient also has an office visit for an unrelated issue on the same day?
You can bill both the biopsy code and the office visit code with modifier 25 on the office visit. The documentation must clearly show that the office visit was for a separate, identifiable issue. For example, the patient came in for a rash on their arms and also had a suspicious mole biopsied. Those are separate problems with separate documentation.
What is the correct way to bill multiple biopsies of the same type?
Use the primary code once and the add on code for each additional biopsy. For three punch biopsies, report 11104 once and 11105 twice. Do not report 11104 three times. That would be incorrect.
Does Medicare cover skin biopsies?
Yes, Medicare covers medically necessary skin biopsies. The patient is responsible for their Part B deductible and 20 percent coinsurance. Prior authorization is generally not required for skin biopsies, but some Medicare Advantage plans may have different rules.
What is the difference between 11104 and 11106?
11104 is a punch biopsy using a circular tool to remove a cylindrical sample. 11106 is an incisional biopsy using a scalpel to remove a larger, often wedge shaped, full thickness sample. Incisional biopsy is considered more invasive and has a higher relative value unit.
What ICD-10 code do I use for a skin biopsy?
There is no single biopsy diagnosis code. You attach the ICD-10-CM code that describes the lesion being biopsied and proves medical necessity. Before pathology returns, that is usually a suspicious lesion finding or a neoplasm of uncertain behavior such as D48.5. After pathology confirms the result, update to the specific diagnosis, for example a C44 code for non-melanoma skin cancer or a D23 code for a benign neoplasm. The claim, the chart, and the path report should all carry the same final diagnosis.
How much does a skin biopsy pay in 2026?
Payment depends on the method. A punch biopsy under 11104 pays roughly 121.85 dollars at the 2026 national non-facility rate, with incisional valued higher and tangential lower, and add-on codes paying a reduced amount per additional lesion. These are national Medicare figures, so confirm your locality-adjusted amount in the CMS Physician Fee Schedule before quoting it.
Final Thoughts
Skin biopsy coding follows three simple rules. Use the method specific code for each technique. Report only one primary code per encounter, choosing the most invasive method. Then use add on codes for every additional biopsy. Tangential is least invasive. Punch is moderate. Incisional is most invasive. Simple closure is bundled into punch and incisional codes. Therapeutic shave removals require shave removal codes, not biopsy codes. Follow these rules and claims pay correctly.
